Company Overview of Advaxis, Inc.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its lead product ADXS-HPV, an Lm-LLO immunotherapy product candidate used for the treatment of human papilloma virus (HPV) associated cancers, completed its Phase II study. The company is also develop...
305 College Road East
Princeton, NJ 08540
Founded in 2002
Key Executives for Advaxis, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $398.8K
Chief Operating Officer and Executive Vice President
Total Annual Compensation: $285.0K
Chief Scientific Officer and Executive Vice President
Total Annual Compensation: $331.2K
Compensation as of Fiscal Year 2014.
Advaxis, Inc. Key Developments
Advaxis, Inc. Announces Executive Changes
May 21 15
Advaxis, Inc. announced that it has appointed Fred J. Frullo as vice president, regulatory affairs. With more than 20 years of experience in the biopharmaceutical industry, Frullo is well versed in the development of global regulatory strategies for the supervision, review and assembly of pharmaceutical product submission and coordination with global health authorities to obtain approvals. As vice president, regulatory affairs, Frullo will oversee regulatory submissions for the company's Lm-LLO cancer immunotherapy clinical programs, including ADXS-HPV, ADXS-PSA and ADXS-HER2, as well as combination studies involving complementary immunotherapy technologies. Frullo will lead the development and submission of all regulatory documents on behalf of Advaxis to the appropriate health agencies and coordinating joint submissions with Advaxis's strategic partners as warranted. In this role, Frullo will succeed Chris L. French, who will now lead the company's compliance program. Frullo was previously the director, global regulatory strategy at Bristol-Myers Squibb, where he was responsible for maintaining regulatory compliance for the oncology portfolio of marketed products and providing global regulatory strategy support for both Life Cycle Management Teams and Early Development Teams.
Advaxis, Inc. and Sorrento Therapeutics, Inc. Form Collaboration to Evaluate Combinations of Advaxis's Lm-LLO Immunotherapy Technology and Sorrento's Immunomodulatory Antibodies
May 19 15
Advaxis, Inc. has entered into a non-exclusive research and clinical trial collaboration agreement with Sorrento Therapeutics, Inc. to evaluate combinations of Advaxis'sLm-LLO cancer immunotherapy technology platform, including ADXS-HPV, ADXS-PSA and ADXS-HER2, with Sorrento's fully human antibodies targeting immune checkpoints, including GITR, OX40, LAG-3 and TIM-3. Sorrento has the diverse fully human antibody libraries in the industry designed to facilitate rapid identification and selection of highly specific therapeutic monoclonal antibody (mAb) product candidates. Advaxis's preclinical program for ADXS-HPV previously examined its therapeutic potential in combination with agonistic research antibodies, including anti-OX40 and anti-GITR. Preclinical data demonstrated that the combination of ADXS-HPV with agonistic research antibodies led to significant inhibition of tumor growth and prolonged survival in tumor-bearing mice. Complete regression of established tumors occurred in 40% and 60% of animals treated with ADXS-HPV in combination with anti-OX40 and anti-GITR antibodies, respectively (AACR Abstract #LB-229 ). Under the terms of the agreement, Advaxis will conduct the studies and the companies will equally share the expenses. The companies hope to commence the first of the two planned combination studies in 2016. Results from the studies will be used to determine whether further clinical development of specific combinations is warranted.
Advaxis, Inc. Appoints Thomas W. Hare as Vice President, Clinical Operations
May 6 15
Advaxis, Inc. announced that it has appointed Thomas W. Hare as Vice President, Clinical Operations. Mr. Hare brings to Advaxis more than 28 years of experience in the biopharmaceutical and contract research organization industries overseeing the management of global commercial and clinical operations, data management, outsourcing and medical writing groups. In his role as Vice President, Clinical Operations, Mr. Hare will report to the company's Executive Vice President, Chief Medical Officer, David J. Mauro, MD, Ph.D., and will oversee clinical operations for the company's multiple Lm-LLO cancer immunotherapy clinical programs. Most recently, Mr. Hare served as Vice President, Drug Development Operations for Incyte Corporation.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|